S&P 500   2,996.37 (+0.01%)
DOW   26,759.59 (-0.11%)
QQQ   191.70 (-0.08%)
FB   185.67 (+1.83%)
MSFT   136.15 (-0.16%)
GOOGL   1,254.39 (+1.06%)
AMZN   1,760.18 (-0.31%)
CGC   21.71 (+2.65%)
MU   44.54 (-0.27%)
BABA   169.11 (-0.46%)
GE   9.09 (+0.33%)
TSLA   253.81 (-0.69%)
T   37.64 (-1.39%)
ACB   3.67 (+2.52%)
NFLX   271.01 (+1.62%)
BAC   31.31 (+0.35%)
GILD   66.48 (+0.94%)
S&P 500   2,996.37 (+0.01%)
DOW   26,759.59 (-0.11%)
QQQ   191.70 (-0.08%)
FB   185.67 (+1.83%)
MSFT   136.15 (-0.16%)
GOOGL   1,254.39 (+1.06%)
AMZN   1,760.18 (-0.31%)
CGC   21.71 (+2.65%)
MU   44.54 (-0.27%)
BABA   169.11 (-0.46%)
GE   9.09 (+0.33%)
TSLA   253.81 (-0.69%)
T   37.64 (-1.39%)
ACB   3.67 (+2.52%)
NFLX   271.01 (+1.62%)
BAC   31.31 (+0.35%)
GILD   66.48 (+0.94%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 EyenoviaCatabasis PharmaceuticalsInfinity PharmaceuticalsMerrimack PharmaceuticalsNovan
SymbolNASDAQ:EYENNASDAQ:CATBNASDAQ:INFINASDAQ:MACKNASDAQ:NOVN
Price Information
Current Price$2.79$4.61$1.10$4.10$2.36
52 Week RangeBuyBuyHoldHoldBuy
Analyst Ratings
Consensus RecommendationBuyBuyHoldHoldBuy
Consensus Price Target$11.50$47.50$3.00N/A$6.00
% Upside from Price Target312.19% upside930.37% upside172.73% upsideN/A154.24% upside
Trade Information
Market Cap$46.03 million$56.71 million$65.01 million$55.85 million$60.22 million
Beta1.131.741.822.191.96
Average Volume92,238152,918159,20456,87344,603
Sales & Book Value
Annual RevenueN/A$500,000.00$22.15 million$144.27 million$5.99 million
Price / SalesN/A107.142.830.3810.27
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.43 per share$4.89 per share$0.92 per share$4.41 per share$0.20 per share
Price / BookN/A0.941.200.9311.80
Profitability
Net Income$-17,250,000.00$-25,870,000.00$-11,250,000.00$-40,510,000.00$-12,670,000.00
EPS($1.82)($5.12)($0.20)N/A($1.13)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-77.80%N/A-363.12%
Return on Equity (ROE)-153.63%-59.06%-42.16%-84.01%-2,067.72%
Return on Assets (ROA)-130.85%-53.31%-28.36%-57.89%-83.07%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.06%N/AN/A
Current Ratio4.13%9.09%7.93%8.61%1.79%
Quick Ratio4.13%9.09%7.93%8.61%1.79%
Ownership Information
Institutional Ownership Percentage8.90%37.63%53.84%48.28%4.80%
Insider Ownership Percentage43.10%3.20%12.12%21.20%5.36%
Miscellaneous
EmployeesN/A24252747
Shares Outstanding16.44 million11.62 million57.03 million13.36 million26.07 million
Next Earnings Date11/12/2019 (Estimated)11/12/2019 (Estimated)11/4/2019 (Estimated)11/6/2019 (Estimated)11/4/2019 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
 EyenoviaCatabasis PharmaceuticalsInfinity PharmaceuticalsMerrimack PharmaceuticalsNovan

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel